Beta-2 adrenergic receptor genetic polymorphisms and asthma

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 6, 2009, Pages 631-643

  Hizawa, N ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Asthma; Beta 2 adrenergic receptor; Gene environmental interaction; Gene gene interaction; Genetic polymorphism; Haplotype

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; GLUCOCORTICOID; PLACEBO; SALBUTAMOL; SALMETEROL;

ASTHMA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHENOTYPE; PREDICTION; REVIEW;

ASTHMA; COST OF ILLNESS; FORCED EXPIRATORY VOLUME; HAPLOTYPES; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2;

EID: 70450208863     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01066.x     Document Type: Review

References (113)

1. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE (2006) Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine, 144, 904 912.
2. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group (2006) The salmeterol multicenter asthma research trial (SMART): a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest, 129, 15 26.
3. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR (1998) Potential masking effects of salmeterol on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine, 158, 924 930.
4. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ (1997) Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. American Journal of Respiratory and Critical Care Medicine, 156, 28 35.
5. Sears MR (1995) Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? No. American Journal of Respiratory and Critical Care Medicine, 151, 600 601.
6. Drysdale CM, McGraw DW, Stack CB et al. (2000) Complex promoter and coding region beta2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proceedings of the National Academy of Sciences of the United States of America, 97, 10483 10488.
7. Silverman EK, Kwiatkowski DJ, Sylvia JS et al. (2003) Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. Journal of Allergy and Clinical Immunology, 112, 870 876.
8. Martinez FD (2005) Safety of long-acting beta-agonists - an urgent need to clear the air. New England Journal of Medicine, 353, 2637 2639.
9. Asthma. http://www.who.int/topics/asthma/en/ (accessed 1 November 2008).
10. Masoli M, Fabian D, Holt S, Beasley R (2004) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy, 59, 469 478.
11. Weiss KB, Sullivan SD (2001) The health economics of asthma and rhinitis. I. Assessing the economic impact. Journal of Allergy and Clinical Immunology, 107, 3 8.
12. Chapman KR, Boulet LP, Rea RM et al. (2008) Suboptimal asthma control: prevalence, detection and consequences in general practice. European Respiratory Journal, 31, 320 325.
13. Accordini S, Corsico A, Cerveri I et al. (2008) The socio-economic burden of asthma is substantial in Europe. Allergy, 63, 116 124.
14. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee (1998) Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet, 351, 1225 1232.
15. ISAAC Steering Committee (1998) Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). European Respiratory Journal, 12, 315 335.
16. Haselkorn T, Lee JH, Mink DR, Weiss ST, TENOR Study Group (2008) Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma. Annals of Allergy, Asthma, and Immunology, 101, 256 263.
17. Davis B, Marin MG, Yee JW, Nadel JA (1979) Effect of terbutaline on movement of Cl- and Na+ across the trachea of the dog in vitro. The American Review of Respiratory Disease, 120, 547 552.
18. Devalia JL, Sapsford RJ, Rusznak C, Toumbis MJ, Davies RJ (1992) The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulmonary Pharmacology, 5, 257 263.
19. 2-adrenoceptors. Journal of Applied Physiology, 65, 700 705.
20. Erjefalt I, Persson CG (1991) Pharmacologic control of plasma exudation into tracheobronchial airways. The American Review of Respiratory Disease, 143, 1008 1014.
21. Butchers PR, Vardey CJ, Johnson M (1991) Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. British Journal of Pharmacology, 104, 672 676.
22. 2 agonists: greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine, 150, 381 387.
23. Green SA, Liggett SB (1996) G-protein-coupled receptor signaling in the lung. In : Liggett S, Meyers D, eds. The Genetics of Asthma. New York : Marcel Dekker, Inc., 67 90.
24. Kamachi A, Munakata M, Nasuhara Y et al. (2001) Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax, 56, 19 24.
25. Tamaoki J, Tagaya E, Kawatani K, Nakata J, Endo Y, Nagai A (2004) Airway mucosal thickening and bronchial hyperresponsiveness induced by inhaled beta 2-agonist in mice. Chest, 126, 205 212.
26. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE (1988) Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet, 1, 554 558.
27. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. New England Journal of Medicine, 327, 1198 1203.
28. O'Connor BJ, Aikman S, Barnes PJ (1992) Tolerance to the non-bronchodilator effects of inhaled beta-2 agonists in asthma. New England Journal of Medicine, 327, 1204 1208.
29. Taylor DR, Town GI, Herbison GP et al. (1998) Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax, 53, 744 752.
30. Taylor DR, Sears MR, Herbison GP et al. (1993) Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax, 48, 134 138.
31. Sears MR, Taylor DR, Print CG et al. (1990) Regular inhaled beta-agonist treatment in bronchial asthma. Lancet, 336, 1391 1396.
32. Drazen JM, Israel E, Boushey HA et al. (1996) Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. New England Journal of Medicine, 335, 841 847.
33. Gauvreau GM, Jordana M, Watson RM, Cockroft DW, O'Byrne PM (1997) Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine, 156, 1738 1745.
34. Manolitsas ND, Wang J, Devalia JL, Trigg CJ, McAulay AE, Davies RJ (1995) Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. American Journal of Respiratory and Critical Care Medicine, 151, 1925 1930.
35. Spitzer WO, Suissa S, Ernst P et al. (1992) The use of beta-agonists and the risk of death and near death from asthma. New England Journal of Medicine, 326, 501 506.
36. Suissa S, Ernst P, Boivin JF et al. (1994) A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. American Journal of Respiratory and Critical Care Medicine, 149, 604 610.
37. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF (2002) Beta-agonist intrinsic efficacy: measurement and clinical significance. American Journal of Respiratory and Critical Care Medicine, 165, 1353 1358.
38. Nelson HS (1995) Beta-adrenergic bronchodilators. New England Journal of Medicine, 333, 499 506.
39. Salpeter SR, Ormiston TM, Salpeter EE (2004) Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Annals of Internal Medicine, 140, 802 813.
40. q receptor signaling via phospholipase C underlies the airway β-agonist paradox. Journal of Clinical Investigation, 112, 619 626.
41. Callaerts-Vegh Z, Evans KL, Dudekula N et al. (2004) Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proceedings of the National Academy of Sciences of the United States of America, 101, 4948 4953.
42. Hanania NA, Singh S, El-Wali R et al. (2008) The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulmonary Pharmacology and Therapeutics, 21, 134 141.
43. 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proceedings of the National Academy of Sciences of the United States of America, 84, 46 50.
44. Postma DS, Bleecker ER, Amelung PJ et al. (1995) Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. New England Journal of Medicine, 333, 894 900.
45. Postma DS, Meyers DA, Jongepier H, Howard TD, Koppelman GH, Bleecker ER (2005) Genomewide screen for pulmonary function in 200 families ascertained for asthma. American Journal of Respiratory and Critical Care Medicine, 172, 446 452.
46. 2 adrenergic receptor in normal and asthmatic subjects. American Journal of Respiratory Cell and Molecular Biology, 8, 334 339.
47. Hawkins GA, Tantisira K, Meyers DA et al. (2006) Sequence, haplotype and association analysis of ADRbeta2 in multi-ethnic asthma case/control subjects. American Journal of Respiratory and Critical Care Medicine, 174, 1101 1109.
48. Munakata M, Harada Y, Ishida T et al. (2006) Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects. Allergology International, 55, 191 198.
49. Green SA, Turki J, Innis M, Liggett SB (1994) Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry, 33, 9414 9419.
50. Green SA, Cole G, Jacinto M, Innis M, Liggett SB (1993) A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. Journal of Biological Chemistry, 268, 23116 23121.
51. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB (1995) Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. American Journal of Respiratory Cell and Molecular Biology, 13, 25 33.
52. McGraw DW, Forbes SL, Kramer LA, Liggett SB (1998) Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. Journal of Clinical Investigation, 102, 1927 1932.
53. 2-Adrenergic receptor 5′ haplotypes influence promoter activity. British Journal of Pharmacology, 137, 1213 1216.
54. Moore PE, Laporte JD, Abraham JH et al. (2000) Polymorphism of the beta(2)-adrenergic receptor gene and desensitization in human airway smooth muscle. American Journal of Respiratory and Critical Care Medicine, 162, 2117 2124.
55. 2-adrenoceptor on desensitization in human lung mast cells. Pharmacogenetics, 10, 153 162.
56. 2-adrenoceptors in asthmatic patients. Chest, 115, 324 328.
57. 2- adrenergic receptor down-regulation. Clinical Pharmacology and Therapeutics, 74, 255 263.
58. Ohe M, Munakata M, Hizawa N et al. (1995) Beta 2 adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma. Thorax, 50, 353 359.
59. 2-adrenoreceptor polymorphism is associated with elevated IgE levels in asthmatic families. Journal of Allergy and Clinical Immunology, 100, 261 265.
60. 2- Adrenergic receptor haplotypes in mild, moderate, and fatal/near fatal asthma. American Journal of Respiratory and Critical Care Medicine, 158, 787 791.
61. 2 adrenoceptor with reported childhood asthma: population based study. British Medical Journal, 316, 664.
62. 2-Adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clinical and Experimental Allergy, 28, 442 448.
63. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R (1997) Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. Journal of Clinical Investigation, 100, 3184 3188.
64. Summerhill E, Leavitt SA, Gidley H, Parry R, Solway J, Ober C (2000) Beta(2)-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. American Journal of Respiratory and Critical Care Medicine, 162, 599 602.
65. 2-adrenoceptor polymorphisms and asthma diagnosis among Mexican adults. Journal of Allergy and Clinical Immunology, 112, 1095 1100.
66. 2-adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. Journal of Clinical Investigation, 95, 1635 1641.
67. 2 adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children. Clinical and Experimental Allergy, 34, 1043 1048.
68. 2-adrenergic receptor polymorphisms with severe asthma. Clinical and Experimental Allergy, 30, 1097 1103.
69. 2-adrenoceptor polymorphisms and asthma: a HuGE review. American Journal of Epidemiology, 162, 201 211.
70. 2-adrenergic receptor polymorphisms with asthma phenotypes. Journal of Allergy and Clinical Immunology, 115, 963 972.
71. Migita O, Noguchi E, Jian Z et al. (2004) ADRB2 polymorphisms and asthma susceptibility: transmission disequilibrium test and meta analysis. International Archives of Allergy and Immunology, 134, 150 157.
72. 2- adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet, 368, 771 779.
73. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA (1999) Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clinical Pharmacology and Therapeutics, 65, 519 525.
74. Palmer LJ, Silverman ES, Weiss ST, Drazen JM (2002) Pharmacogenetics of asthma. American Journal of Respiratory and Critical Care Medicine, 165, 861 866.
75. Sin DD, Man J, Sharpe H, Gan WQ, Man SF (2004) Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. The Journal of American Medical Association, 292, 367 376.
76. Drazen JM, Silverman EK, Lee TH (2000) Heterogeneity of therapeutic responses in asthma. British Medical Bulletin, 56, 1054 1070.
77. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet, 350, 995 999.
78. Choudhry S, Ung N, Avila PC et al. (2005) Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. American Journal of Respiratory and Critical Care Medicine, 171, 563 570.
79. Taylor DR, Epton MJ, Kennedy MA et al. (2005) Bronchodilator response in relation to β-adrenoceptor haplotype in patients with asthma. American Journal of Respiratory and Critical Care Medicine, 172, 700 703.
80. Hizawa N, Makita H, Nasuhara Y et al. (2007) Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest, 132, 1485 1492.
81. Israel E, Drazen JM, Liggett SB et al. (2000) The effect of polymorphisms of the beta(2) adrenergic receptor on the response to regular use of albuterol in asthma. American Journal of Respiratory and Critical Care Medicine, 162, 75 80.
82. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI (2000) Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax, 55, 762 767.
83. Israel E, Chinchilli VM, Ford JG et al. (2004) Use of regularly scheduled albuterol treatment in asthma: genotype stratified, randomized placebo-controlled cross-over trial. Lancet, 364, 1505 1512.
84. Wechsler ME, Lehman E, Lazarus SC et al. (2006) β-Adrenergic receptor polymorphisms and response to salmeterol. American Journal of Respiratory and Critical Care Medicine, 173, 519 526.
85. 2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax, 61, 940 944.
86. Isada A, Hizawa N, Shimizu K et al. (2008) The Arg16Glybeta2-adrenergic receptor polymorphism influences long term clinical responses to beta2-agonist. Arerugi, 57, 713 721 (Article in Japanese).
87. 2-adrenergic receptor genotype in subjects with persistent asthma. Journal of Allergy and Clinical Immunology, 118, 809 816.
88. 2-agonist therapy. Lancet, 370, 2118 2125.
89. Fowler SJ, Dempsey OJ, Sims EJ et al. (2000) Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. American Journal of Respiratory and Critical Care Medicine, 162, 1318 1322.
90. Hall IP, Wheatley A, Wilding P, Liggett SB (1995) Association of Glu27 beta-2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet, 345, 1213 1214.
91. Ramsay CE, Hayden CM, Tiller KJ, Burton PR, Goldblatt J, LeSouef PN (1999) Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway reactivity. Clinical and Experimental Allergy, 29, 1195 1203.
92. 2-adrenoceptor (ADRB2) haplotypes. American Journal of Respiratory and Critical Care Medicine, 158, 1968 1973.
93. 2-adrenoceptor variants with bronchial hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine, 161, 469 474.
94. 2-Adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest, 126, 66 74.
95. Fukui Y, Hizawa N, Takahashi D, Maeda Y, Jinushi E, Konno S, Nishimura M (2006) Association between nonspecific airway hyper-responsiveness and Arg16Gly beta2-adrenergic receptor gene polymorphism in asymptomatic healthy Japanese subjects. Chest, 130, 449 454.
96. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB (2005) Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Human Molecular Genetics, 14, 1671 1677.
97. Wang WC, Mihlbachler KA, Bleecker ER, Weiss ST, Liggett SB (2008) A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenetics and Genomics, 18, 729 732.
98. Litonjua AA, Lasky-Su J, Schneiter K et al. (2008) ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. American Journal of Respiratory and Critical Care Medicine, 178, 688 694.
99. Poon AH, Tantisira KG, Litonjua AA et al. (2008) Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenetics and Genomics, 18, 373 382.
100. Meyers DA, Postma DS, Stine OC et al. (2005) Genome screen for asthma and bronchial hyperresponsiveness: interactions with passive smoke exposure. Journal of Allergy and Clinical Immunology, 115, 1169 1175.
101. Wang Z, Chen C, Niu T et al. (2001) Association of asthma with beta(2)-adrenergic receptor gene polymorphism and cigarette smoking. American Journal of Respiratory and Critical Care Medicine, 163, 1404 1409. (Pubitemid 32506607)
102. Wang C, Salam MT, Islam T, Wenten M, Gauderman WJ, Gilliland FD (2008) Effects of in utero and childhood tobacco smoke exposure and beta2-adrenergic receptor genotype on childhood asthma and wheezing. Pediatrics, 122, e107 e114.
103. Zhang G, Hayden CM, Khoo SK et al. (2007) Beta2-adrenoceptor polymorphisms and asthma phenotypes: interactions with passive smoking. European Respiratory Journal, 30, 48 55.
104. Schuller HM, Tithof PK, Williams M, Plummer H III. (1999) The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Research, 59, 4510 4515.
105. Ning W, Li CJ, Kaminski N et al. (2004) Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 101, 14895 14900.
106. Homa DM, Mannino DM, Lara M (2000) Asthma mortality in US: Hispanics of Mexican, Puerto Rican, and Cuban heritage, 1990-1995. American Journal of Respiratory and Critical Care Medicine, 161, 504 509.
107. Liggett SB (2002) Polymorphisms of the beta2-adrenergic receptor. New England Journal of Medicine, 346, 536 538.
108. Lee DK, Bates CE, Lipworth BJ (2004) Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27. British Journal of Clinical Pharmacology, 57, 100 104.
109. Laporte JD, Moore PE, Panettieri RA, Moeller W, Heyder J, Shore SA (1998) Prostanoids mediate IL-1β-induced β-adrenergic hyporesponsiveness in human airway smooth muscle cells. American Journal of Physiology, 275, L491 L501.
110. Judson R, Stephens JC, Windemuth A (2000) The predictive power of haplotypes in clinical response. Pharmacogenomics, 1, 15 26.
111. Oostendorp J, Postma DS, Volders H et al. (2005) Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes. American Journal of Respiratory and Critical Care Medicine, 172, 322 328.
112. Kay LJ, Rostami-Hodjegan A, Suvarna SK, Peachell PT (2007) Influence of beta(2)-adrenoceptor gene polymorphisms on beta(2)-adrenoceptor-mediated responses in human lung mast cells. British Journal of Pharmacology, 152, 323 331.
113. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S (2008) Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Annals of Internal Medicine, 149, 33 42.